Search results
Showing 1 to 15 of 69 results for parkinson
This quality standard covers the management of Parkinson’s disease in adults. It does not include treatment of parkinsonism not caused by Parkinson’s disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS164Show all sections
Sections for QS164
- Quality statements
- Quality statement 1: Point of contact with specialist services
- Quality statement 2: Information about impulse control disorders
- Quality statement 3: Referral to physiotherapy, occupational therapy or speech and language therapy
- Quality statement 4: Levodopa in hospital or a care home
- Quality statement 5: Access to clozapine for treating hallucinations and delusions
- About this quality standard
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)
Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.
This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.
Evidence-based recommendations on subthalamotomy for Parkinson's disease. This involves putting very thin needles into the brain through small holes made in the skull.
View recommendations for IPG65Show all sections
Sections for IPG65
All NICE products on parkinson's disease, tremor and dystonia. Includes any guidance, advice and quality standards.
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
Path Finder for freezing of gait in people with Parkinson's disease (MIB170)
NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease
Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson’s disease in adults. This involves applying ultrasound to a specific area on 1 side of the brain (thalamus).
View recommendations for IPG606Show all sections
Awaiting development [GID-IPG10375] Expected publication date: 12 December 2024
Suggested remit: To appraise the clinical and cost effectiveness of levodopa, carbidopa monohydrate and entacapone within its marketing authorisation for treati...
Evidence-based recommendations on deep brain stimulation for Parkinson's disease. This involves planting electrodes into the brain and generating electrical currents to reduce the problems caused by Parkinson's disease
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (IPG188)
Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.
View recommendations for IPG188Show all sections
Sections for IPG188
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.